| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
This compound has specific biological targets as a GABA receptor modulator. It is a full agonist at the human recombinant ρ1 GABAC receptor and a modulator of GABAA and GABAB receptors. The (R)-configuration is essential for potent GABAB receptor interaction, with the (R)-enantiomer demonstrating significantly higher inhibitory potency than the (S)-enantiomer in GABAB binding assays. This compound is utilized in neuroscience research to investigate GABAergic neurotransmission.
|
|---|---|
| ln Vitro |
Commercial ergot supplements have been made from amino acids and their derivatives. They affect the release of anabolic hormones, the availability of fuel for activity, the ability to think clearly under pressure, and the prevention of muscular damage brought on by exertion. They are regarded as advantageous synergistic food ingredients [1].
In vitro, this compound acts as a full agonist at human recombinant ρ1 GABAC receptors (EC50 19 µM for WT; retains agonism in T244S mutant where (S)-enantiomer is antagonist). It also modulates GABAA and GABAB receptor activity. The compound is used in neuroscience research to investigate GABAergic neurotransmission in in vitro receptor studies. It has superior GABAB binding inhibition vs. the (S)-isomer for unambiguous receptor assignment. |
| ln Vivo |
This compound has been studied in vivo for its effects on GABAergic neurotransmission. It is utilized in neuroscience research to investigate GABAergic neurotransmission in in vivo models of neurological function. The enantiopure (R)-form is essential for studies requiring selective GABAB receptor modulation without confounding GABAA activity from the (S)-enantiomer. The compound has applications in the synthesis of bioactive peptides and studies related to neurotransmitter regulation and metabolic pathways.
|
| Enzyme Assay |
In vitro receptor binding assays for (R)-3-Amino-4-hydroxybutanoic acid typically involve testing against GABAA, GABAB, and GABAC receptors. A standard protocol involves using the compound as a tool to study GABAergic neurotransmission in receptor binding studies. The (R)-enantiomer demonstrates superior GABAB binding inhibition vs. the (S)-isomer for unambiguous receptor assignment. It can be used as a full agonist at ρ1 GABAC receptors.
|
| Cell Assay |
This compound is not typically used in standard cell-based assays as a therapeutic agent, but rather as a pharmacological tool compound. It is utilized in neuroscience research to investigate GABAergic neurotransmission. It should be stored under appropriate conditions. Purity is typically ≥98%. It is soluble in water and common organic solvents. The product is for research purposes only and is not intended for human or veterinary use.
|
| Animal Protocol |
In vivo, this compound is used in neuroscience research to investigate GABAergic neurotransmission in animal models of neurological function. The enantiopure (R)-form is essential for studies requiring selective GABAB receptor modulation. It has applications in the synthesis of bioactive peptides and studies related to neurotransmitter regulation. However, it is not a therapeutic agent itself.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of (R)-3-Amino-4-hydroxybutanoic acid are not extensively documented as it is not a drug. It is a small molecule (MW 119.12 g/mol) with the formula C4H9NO3. As a GABA receptor modulator, it may have limited bioavailability due to its polar nature. Detailed ADME studies are limited as the compound is primarily used as a research tool.
|
| Toxicity/Toxicokinetics |
The toxicity of (R)-3-Amino-4-hydroxybutanoic acid is not extensively documented, as it is a research chemical not intended for human or veterinary use. It should be handled with standard laboratory precautions, including the use of appropriate personal protective equipment and working in a well-ventilated area. The compound is a solid at room temperature. It is not intended for diagnostic, therapeutic, or other medical applications.
|
| References | |
| Additional Infomation |
(3R)-3-amino-4-hydroxybutyric acid is a β-amino acid formed by replacing the amino group at the 3-position and the hydroxyl group at the 4-position of butyric acid. It is a β-amino acid and also a hydroxy monocarboxylic acid.
(R)-3-Amino-4-hydroxybutanoic acid (L-β-homoserine) is a chiral β-amino acid that functions as a full agonist at human recombinant ρ1 GABAC receptors and a modulator of GABAA and GABAB receptors. The enantiopure (R)-form is essential for studies requiring selective GABAB receptor modulation. It is utilized in neuroscience research to investigate GABAergic neurotransmission. This compound is not a pharmaceutical and has no clinical trials or approved therapeutic status. |
| Molecular Formula |
C4H9NO3
|
|---|---|
| Molecular Weight |
119.12
|
| Exact Mass |
119.058
|
| CAS # |
16504-56-6
|
| PubChem CID |
1502076
|
| Appearance |
White to off-white solid powder
|
| Density |
1.3±0.1 g/cm3
|
| Boiling Point |
374.5±32.0 °C at 760 mmHg
|
| Flash Point |
180.3±25.1 °C
|
| Vapour Pressure |
0.0±1.9 mmHg at 25°C
|
| Index of Refraction |
1.511
|
| LogP |
-1.15
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
8
|
| Complexity |
83.4
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
C([C@H](CO)N)C(=O)O
|
| InChi Key |
BUZICZZQJDLXJN-GSVOUGTGSA-N
|
| InChi Code |
InChI=1S/C4H9NO3/c5-3(2-6)1-4(7)8/h3,6H,1-2,5H2,(H,7,8)/t3-/m1/s1
|
| Chemical Name |
(3R)-3-amino-4-hydroxybutanoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 8.3949 mL | 41.9745 mL | 83.9490 mL | |
| 5 mM | 1.6790 mL | 8.3949 mL | 16.7898 mL | |
| 10 mM | 0.8395 mL | 4.1974 mL | 8.3949 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
